Background: Muscle sympathetic nerve firing rate increases as chronic heart failure (CHF) progresses, yet its oscillation, particularly within the frequency range encompassing 0.13 Hz, diminishes. The current study tested the hypothesis that chronic therapy with lipophilic β-adrenoceptor antagonists augments the modulation of muscle sympathetic nerve activity variability (MSNAV) at this frequency range.
our classical 'time domain' characteristics of chronic heart failure (CHF) linked to adverse prognosis are increased plasma norepinephrine (NE) concentration, greater cardiac NE spillover, decreased reflex vagal control of heart rate (HR), and abnormal 123 I-metaiodobenzyl-guanidine washout rate. 1-3 It is now appreciated that 'frequency domain' or power spectral markers of autonomic circulatory regulation, such as decreased HR variability, also are associated with premature mortality. 1, 4 In advanced CHF, however, HR variability provides only indirect and often imperfect information concerning efferent sympathetic or vagal discharge directed at the sino-atrial node. 5 By contrast, microneurography quantifies directly the sympathetic outflow to skeletal muscle. Conventional multifiber microneurographic recordings integrate into envelopes of pulse-synchronous bursts firing of post-ganglionic single fibers that may remain silent or discharge one or more times, during a single cardiac cycle. Because burst amplitude is a function of all single fiber discharges detected and integrated during each cardiac cycle, 6 when compared with HR variability, which is derived solely from beat-to-beat oscillations in cycle length, burst amplitude adds an additional dimension of complexity to analysis of muscle sympathetic nerve activity (MSNA) variability within the frequency domain. 7 Worsening of CHF is characterized by a progressive increase in muscle sympathetic nerve discharge frequency, due to higher firing rates of individual fibers plus recruitment of previously silent fibers 1,6 resulting in incessant and invariant sympathetic outflow within the low frequency (LF) range encompassing 0.13 Hz, where, as identified optimally by coarse graining spectral analysis (CGSA), 7 oscillations in MSNA diminish or disappear. 8, 9 This progression cannot be explained by impaired arterial baroreflex modulation of central sympathetic outflow. 7 The LF component of systolic blood Beta-Blockade and Sympathetic Rhythmicity in CHF pressure (BP) variability (ie, Meyer waves) is preserved in CHF, 10 and the gain of the transfer function relating LF BP variations into LF MSNA oscillations is similar in healthy and heart failure subjects. Attributed instead to saturation of central systems responsible for the regulation of sympathetic nerve discharge oscillating at this frequency by the excitatory neurohumoral milieu of CHF, such loss of MSNA spectral power has been suggested to have independent adverse prognostic implications. 8 LF modulation of MSNA can be restored by cardiac transplantation or by the acute infusion of atrial natriuretic peptide. In both examples, such augmentation occurs in the absence of any change in sympathetic burst frequency, 11, 12 underscoring the difference in the mechanisms responsible for MSNA firing rate and for MSNA variability.
Placebo-controlled trials involving patients with symptomatic heart failure due to left ventricular systolic dysfunction have demonstrated reductions in mortality, morbidity and hospitalizations with both the β-1 selective antagonist metoprolol, and the non-selective antagonist carvedilol. [13] [14] [15] Although neither carvedilol nor metoprolol lower sympathetic burst frequency in CHF, 16 there are no data describing the impact of chronic treatment with these β-adrenoceptor antagonists on MSNA spectral power. Because lipophilicity, 17-19 resulting in central nervous system penetration, 20,21 is a characteristic common to both β-blockers we set out to test the primary hypothesis that in CHF chronic β-blockade with these agents augments harmonic MSNA spectral power, particularly within the frequency range encompassing 0.13 Hz. Our secondary objective was to determine whether β-1 antagonism, with metoprolol, is sufficient to demonstrate this effect.
Methods

Participants
Patients with symptomatic CHF (New York Heart Association, NYHA, class II or III), secondary to ischemic or idiopathic cardiomyopathy, were recruited. Inclusion criteria included: stable medical therapy for >1 month, left ventricular ejection fraction (EF) <35%, and no prior β-blockade. Exclusion criteria included: recent (<3 months) acute coronary syndrome, primary valvular disease, contraindications to β-blockade, systolic BP <85 mmHg, and resting HR <60 beats/min. This study was one aspect of a larger protocol approved by the University of Toronto Human Subjects Review Committee. 16 Prior publication of placebo-controlled systolic heart failure trials demonstrating reductions in mortality with both β-1 selective and non-selective adrenoceptor blockade 13,22,23 precluded, on ethical grounds, randomization to placebo. Informed written consent was obtained from all subjects.
Procedures
Studies were performed in the same quiet, temperature-controlled room at the same time of the day. Patients rested supine while BP was measured each minute from the right arm by an automatic cuff recorder (Critikon, Dinamap 1846 SX, USA), and also continuously from a finger of the left hand (Ohmeda 2300 Finapres, Englewood, CO, USA). HR was derived from lead II of the electrocardiogram and spontaneous breathing was confirmed by a pneumobelt. MSNA was recorded from the right peroneal nerve using the microneurographic technique. 7
Protocol
After instrumentation, subjects lay quietly for 15 min before the acquisition of at least 7 min of baseline data free from ven-tricular ectopy. All signals were recorded continuously onto paper and by computer. This protocol was replicated after 4 months of β-blockade.
After the first experimental session, patients were randomized in a double-blind fashion to receive either carvedilol or metoprolol tartrate, in addition to their previous treatment. Those allocated to carvedilol received an initial dose of 3.125 mg b.i.d. Those randomized to metoprolol began with 6.25 mg b.i.d. Patients were re-assessed weekly over the next month. Doses were doubled if there was no clinical evidence of worsening CHF, HR was >65 beats/min, and systolic BP was >85 mmHg. Target dosages were carvedilol 25 mg b.i.d. or metoprolol 50 mg b.i.d. Once achieved, patients were reassessed monthly. The assigned drug was taken also on the follow-up morning.
Data Analysis
Ventricular ectopy, signal to noise ratios less than 3:1, and an unstable recording site were important exclusion criteria for MSNA analysis. Multi-fiber MSNA in the time domain was expressed as both burst frequency (bursts/min) and burst incidence (bursts/100 cardiac cycles).
Superimposed upon harmonic central neural contributions to HR and MSNA variability is a broadband non-harmonic noise that is fractal in nature (1/f, where f represents frequency), exhibiting greatest spectral power within the very low and LF ranges. 7,24 CGSA extracts mathematically the non-harmonic from the harmonic components of this signal, permitting discrete analysis of the harmonic components of MSNA variability. 24 This method is particularly relevant to CHF studies. 7 With CGSA, approximately 29% of the variability of MSNA between 0.0 and 0.5 Hz exhibits harmonic oscillation. 7 Compared, however, to the high frequency (HF) range, in which CHF is associated with similar qualitative reductions in MSNA variability using CGSA and Fast Fourier Transformation (FFT), CGSA reveals far greater diminution of LF MSNA (-71%) than detected using FFT (-34%). 7 Because the purpose of the present investigation was to determine the impact of chronic β-adrenoceptor blockade on the harmonic rhythmicity of sympathetic outflow, and because the prior observation upon which the present analysis was based was derived using CGSA, the confounding influence of non-harmonic power was removed in the present analysis by using CGSA exclusively to analyze MSNA within the frequency domain.
Using previously published methods, 7,10,11 7-min segments of the integrated mean voltage neurogram, free of ventricular ectopy, were sampled at a frequency of 200 Hz. For HR the identical time period was sampled at a frequency of 1,000 Hz. The MSNA burst amplitude was normalized with the highest burst referenced at 100 U. The processed signal was passed through a 5 th -order digital low-pass filter (<0.7 Hz) and resampled at 5 Hz to submit the analysis of changes in normalized MSNA as an envelope within the frequency range (0-0.5 Hz) applied conventionally to the spectral analysis of HR. The data set was subdivided into 7 segments, each containing 512 points, with one-half overlapping of each segment. The linear trend was subtracted from the data set in each segment. A Blackman -Harris window was applied to minimize spectral leakage. The power spectrum for each segment was composed over 7 segments to reduce spectral variance. Similar processing was performed on the HR signal. 7 The fractal component was removed next. 7, 24 Residual MSNA harmonic power was determined for each 0.01 Hz increment from 0 to 0.50 Hz and also averaged across (ie, within) con-KUBO T et al. 
Statistical Analysis
Values are expressed as mean ± SE. A value of P<0.05 was required for statistical significance. Baseline physiological and pharmacological characteristics of the 2 subject groups were compared using the unpaired t-test and the Fisher's exact test. When data were distributed normally, paired t-tests were used for within-group before and 4 months after β-blockade comparisons of time domain values. These were also used for mean MSNA and HR spectral power values averaged across pre-specified frequency bands. Wilcoxon's rank sum test was applied whenever tests of normality failed.
As the purpose of this investigation was to test the primary hypothesis that in CHF chronic β-blockade with these agents augments harmonic MSNA spectral power, particularly within the frequency range encompassing 0.13 Hz, the effect of β-blockade on MSNA spectral power for each 0.01 Hz frequency increment over the complete range of 0 to 0.5 Hz was evaluated also as a continuous variable by a series of repeated measures mixed linear model analyses, using SAS v9.2 (SAS Institute, Cary, NC, USA). To mitigate potential problems with linearity, models were run for the 0.1-0.22 Hz range of particular interest, where there was a fairly linear relationship, as well as for each of the 3 conventional spectral bands, and for total spectral power. The compound symmetry method was used in all analyses for the within-subject variance co-variance matrix. The main effects tested were treatment (yes/no; reported as 'time'), drug (carvedilol or metoprolol), and frequency (Hz), and their interactions. If the 3-way interaction (treatment ('time') × drug × frequency) was not significant, this term was removed from the model and the analysis re-run to establish the main effects and all 2-way interactions.
Results
Participants
We recruited 36 patients with a mean age of 54.6±1.8 years and with a mean EF of 19±1%. Of these, 18 were randomized to each β-blocker. All patients were receiving angiotensin converting enzyme (ACE) inhibitors. Background medical therapy was not altered through the course of this study, and no cardiac devices were implanted between the first and second sessions.
In 4 subjects (2 carvedilol), we could not record high quality MSNA at baseline. These subjects were not re-tested. One carvedilol treated patient died 1 month after randomization. One patient in the metoprolol group was non-compliant. Five patients (1 carvedilol) refused restudy. The remaining 25 (14 in the carvedilol group) participated in both study sessions. High quality MSNA could not be obtained during the second study in 4 of these subjects (1 carvedilol). Paired information was therefore available from 21 (13 carvedilol) subjects. There were no significant differences between these 2 groups with respect to baseline characteristics ( Table 1) . Average daily doses of β-blocker in the remaining participants were: carvedilol 43±4 mg/day and metoprolol 63±12 mg/day.
Effects of β-Adrenergic Blockade
Each β-adrenoceptor blocker decreased HR significantly, but neither drug altered BP or MSNA ( Table 2) . There was no between-group difference with respect to these variables. Figure 1 illustrates mean values for harmonic MSNA power for each 0.01-Hz increment for all subjects in the absence and presence of β-adrenoceptor blockade. Before treatment, there was a small peak around 0.03 Hz and a gradual reduction at higher frequencies. As noted previously (compared with control subjects with normal ventricular systolic function), 7,8 MSNA harmonic power in this CHF population was virtually absent at frequencies surrounding 0.13 Hz, cor- responding to an oscillatory cycle length of 7-8 s. There was a second peak in MSNA spectral power at around 0.3 Hz, with progressively greater power at higher frequencies.
Beta-blockade increased mean values for total MSNA spectral power (from 0.00 to 0.50 Hz; 5.2±0.8 to 6.8±1.2 U 2 ;
P<0.001) as well as mean values for average spectral power within the high and the low, but not the very low frequency bands ( Table 3) .
Beta-blockade had no effect on the 0.03 and 0.3 Hz peaks, but increased MSNA spectral power at the 0.13 Hz nadir and Figure 1 . Mean values (standard errors) for muscle sympathetic nerve activity (MSNA) harmonic power derived using coarse graining spectral analysis before (yellow circles) and after (green circles) β-adrenoceptor blockade (n=21), which increased MSNA spectral power at its 0.13 Hz nadir and adjacent frequencies.
There is a significant increase (P<0.003) in MSNA harmonic power across the frequency range of 0.1-0.22 Hz, which encompasses conventional low frequency (0.05-0.15 Hz) and high frequency (0.15-0.50 Hz) spectral bands), but not beyond 0.22 Hz. The effect of each β-adrenoceptor antagonist upon spectral power within frequency deciles is presented in Figure 2 . Similar divergence of these frequency-power relationships Table 5 ). As with the entire cohort, β-blockade increased MSNA variability across the 0.1-0.22 Hz frequency range, from 0.46±0.10 to 1.41±0.39 U 2 (F =8.75; P=0.003). Although there was a significant frequency × drug interaction (F =6.88; P=0.009), consistent with a difference between responses to the 2 β-adrenoceptor antagonists across this specific frequency spectrum, there was no significant treatment × frequency × interaction (F =0.09; P=0.762). By contrast, β-blockade had no effect on the variability of HR across this 0.1-0.22 Hz frequency range (from 12.1±7.5 to 94.6±43.6 ms 2 ; P=0.175) or within VLF or LF bands, but did increase HF HR variability ( Table 3) . Betablockade augmented the total MSNA spectral power (from 4.25±0.63 to 6.25±1.43 U 2 ; F =4.6; P=0.032) and the power within the low (F =39.4; P<0.001), but not the very low (F = 0.01; P=0.911), frequency band. At high frequencies, there was a significant treatment × frequency × drug interaction (F = 4.73; P=0.03) with metoprolol having a greater effect than carvedilol ( Table 5 ).
Discussion
The capacity of the cardiovascular system to respond robustly and appropriately to maintain cardiovascular stability in the face of external challenges is an indication of circulatory health. Contemporary CHF therapy may reduce cardiovascular event rates in part by restoring autonomic regulation of the heart and circulation. Most attention thus far has been directed at indices of tonic and reflex vagal HR modulation. Oscillations in sympathetic outflow to the ventricles, kidney, and peripheral vasculature have received less attention, despite the striking reduction in harmonic MSNA power evident within the region of 0.13 Hz, 7,8,11 even in the presence of optimal ACE inhibition. 11 The key finding in the present CHF study was that 4 months of lipophilic β-blockade with metoprolol, a β-1 adrenoceptor antagonist or carvedilol, a non-selective β-antagonist with acute α-blocking properties, had no effect on efferent post-ganglionic multi-fiber muscle sympathetic burst frequency, yet restored harmonic MSNA spectral power across the frequency range of 0.1-0.22 Hz (Figure 1) . By contrast, βblockade had no effect on HR spectral power across this 0.1-0.22 Hz frequency range. Therefore rather than resulting from a generalized effect of β-blockade on all neural-cardiovascular oscillations, this action, which extends across conventional LF and HF spectral ranges, is specific to the variability of MSNA. These results indicate that chronic βadrenoceptor blockade with these 2 antagonists augments tonic or reflex modulation of discharge within single efferent sympathetic fibers, allowing normal oscillations in multifiber burst amplitude to re-emerge following therapy. Importantly, there was no significant difference between these 2 β-blockers with respect to this particular finding, indicating that β-1 antagonism is sufficient for such augmentation.
While the variability of HR and BP can be determined simply and non-invasively, 10 oscillations in central sympathetic outflow can only be appreciated via continuous direct microneurographic recordings. In people with normal ventricular systolic function, studied during supine rest and breathing spontaneously, MSNA spectral power is distributed relatively evenly across all frequency ranges. 7 In response to the hypotensive stimulus of sodium nitroprusside, LF MSNA power increases, in parallel with the sympathetic nerve firing rate and HR, whereas high-frequency spectral power diminishes. Similar hypotension, elicited by infusion of the α-adrenoreceptor antagonist phentolamine, increased the subjects' HR and the product of MSNA burst frequency and amplitude in the time domain increased 3-fold, yet markedly the LF MSNA spectral power was suppressed. 9 Otherwise healthy subjects with orthostatic syncope also manifested a reduction, of 75%, rather than an increase in LF MSNA spectral power during laboratory tilt testing. 25 This suggests that the absence of spectral power within the LF range may be a marker of impaired neurogenic homeostatic mechanisms.
Discordant responses are also observed in healthy subjects after the acute intravenous administration of atenolol: HR decreases and MSNA increases, but LF MSNA spectral power falls. 26 The preceding observations illustrate 2 important con- cepts: the first is that changes in MSNA spectral power are not a simply a function of changes in HR; and the second is that interventions can exert distinctly different effects upon time and frequency domain representations of multi-fiber MSNA. Values such as burst incidence or frequency, or the product of burst frequency × amplitude, document the number of cardiac cycles in which the firing of one or more single fibers is detected, whereas MSNA power spectra characterize, by integration, the capacity of central or ganglionic influences to modulate the single fiber discharge that summates to form the multi-fiber burst envelope. Impairment of signal transduction within the 0.05-0.15 Hz range at any point in the loop, MSNA → BP → baroreceptors → central nervous system → MSNA, will reduce its LF variability. In CHF, the gain of the transfer function from BP → MSNA within the LF range is preserved, whereas the gain of the transfer function from MSNA → BP across the LF range is attenuated significantly. 7 Because the frequency response characteristics of vascular resistance vessels to neurally released NE cause the MSNA → BP component of this loop to act as a low-pass filter, 27 and the transfer functions relating BP → MSNA and MSNA → BP within the HF range are preserved, the most plausible explanation for the loss of MSNA spectral power in CHF within the 0.13 Hz LF range is impairment of α-adrenoceptor mediated neuroeffector transduction. 7 The observation that LF spectral power in healthy subjects is attenuated by the α-adrenoceptor antagonist, phentolamine, 9 is consistent with this conclusion. In this context it is important to emphasize that a key strength of the present experiment is that repeat studies were not performed until a mean of 4 months after initiating therapy, at which time the peripheral α-adrenoceptor antagonist properties of carvedilol had dissipated. 28 Chronic β-blockade in CHF might augment MSNA spectral power at 1 or more of the transduction points in this closed loop. It is evident, however, that the potential role of breathing patterns, BP variability, and the arterial baroreflex regulation of MSNA in restoring the variability of MSNA can be eliminated, or discounted, because the disappearance of LF spectral power at 0.13 Hz in CHF is unrelated to the frequency of breathing; 7 the variability of systolic BP in βblockade naïve CHF patients is identical to that of sex-and age-matched healthy control subjects 10 (and would not be anticipated to change with β-blockade 29 ); the arterial baroreflex gain, as represented by the power spectral transfer functions relating BP → baroreceptors → central nervous system → MSNA within the very LF, LF and HF ranges is not attenuated, but preserved in CHF and control subjects, 7 and in the present cohort, these transfer functions within the very LF, LF, and HF ranges, reflecting arterial baroreflex regulation of MSNA, were not affected by either carvedilol or metoprolol. 30 A generalized reduction in sodium and water retention might improve neuroeffector transduction, or attenuate sympatho-excitatory input from cardiac and pulmonary afferent fibers stimulated by the elevated filling pressures of severe heart failure. 31 Left and right atrial pressures in our patients, however, were not elevated before randomization, and were not lowered by chronic β-adrenoceptor blockade. 16 Moreover, in our previous experiments in patients with CHF, infusion of atrial natriuretic peptide improved LF MSNA spectral power (without affecting MSNA burst frequency) yet nitroglycerin, administered as a time and hemodynamic control, also lowered systemic and cardiac filling pressure, but had no effect on the MSNA power spectrum. 11 Neither infusion altered HR. Finally, our previous finding (in a larger cohort from the present trial) that β-adrenoceptor antagonism did not increase the gain of the neuroeffector transfer function (MSNA → BP) 28 indicates that this mechanism cannot account for the restoration of MSNA power observed in the present series.
In summary, restoration in MSNA spectral power observed in the present experiments cannot be attributed primarily to enhanced arterial baroreceptor-mediated gain in response to BP oscillations, entrainment of sympathetic outflow in parallel with increases in HR spectral power, or improved neuroeffector transduction. However, because both antagonists increased these patients' stroke volume and pulse pressure 16 it is possible that clinical improvement resulting from chronic β-blockade contributed to the observed restoration of MSNA spectral power, independently of any increase in burst frequency or burst incidence.
Van de Borne et al proposed alterations in the central regulation of sympathetic nerve discharge at this specific frequency as a mechanism for their CHF patients' loss of LF MSNA. 8 Could central nervous system β1-adrenoceptor blockade account for the present finding? Chronic β-blockade in CHF has beneficial effects on hemodynamics, mortality, morbidity, and hospitalization rates, and also reduces the risk of sudden cardiac death. 13,15,17 Results from several large clinical outcome trials suggest that lipophilic β-blockers, with greater capacity for central nervous system penetration, may be superior to hydrophilic β-blockade in achieving such outcomes. 18 Of note, when given acutely to healthy subjects, the hydrophilic β-blocker atenolol decreased LF MSNA power, opposite to our present findings. 26 Although the exact mechanisms responsible for the present observations cannot be determined definitively from these human experiments, these findings are consistent with the concepts that central sympatho-modulatory mechanisms are overwhelmed in CHF, and that this saturation can be alleviated by chronic β-adrenoceptor blockade. Indeed, the presence of β-adrenoceptors in and near brain areas involved in the generation of adrenergic rhythms provides potential central neural pathways by which increased adrenergic neurotransmission might lead to incessant sympathetic outflow, and by which lipophilic β-adrenoceptor antagonists might enhance the modulation of sympathetic outflow across the observed frequency range. [32] [33] [34] In theory, central modulation of sympathetic outflow should confer at least 3 benefits beyond those of peripheral (cardiac) β-adrenoceptor blockade. First, the latter leaves α-adrenoceptor mediated vasoconstriction and consequent renal sodium retention unopposed, and the heart and vasculature unprotected from the vasoconstrictor actions of other sympathetic neurotransmitters, such as neuropeptide Y and adenosine triphosphate. Second, peripheral β-blockade would not restore the normal intrinsic oscillations of sympathetic discharge to the ventricles, or to the kidney or other vascular beds, whereas attenuation of incessant sympathetic drive to the heart, by recovery of such oscillations, might diminish the risk of sudden death. Third, as demonstrated in an experimental canine preparation, 35 neurogenic induction of BP oscillations within this LF range may augment the bioavailability of nitric oxide and increase urinary sodium and water excretion in this condition which is characterized by chronic congestion. Importantly, neither drug in the present investigation caused central 'sympatholysis', a property attributed to bucindolol to account for the singular lack of mortality benefit in a randomized controlled heart failure trial of this non-selective β-adrenoceptor antagonist. 36 
Beta-Blockade and Sympathetic Rhythmicity in CHF
No placebo control group could be studied, for ethical considerations. However, in our previous experiments, nitroglycerin infusion had no effect on harmonic MSNA variability within the LF range inhibition. 11 In the study by Cogliati et al, atenolol acutely increased MSNA but reduced LF MSNA spectral power. 26 The same changes were observed with phentolamine. 9 These previous findings, plus the selective effect of the present interventions on this discrete component only of the MSNA spectrum makes it highly unlikely that the present observation represents a simple chance effect, or the influence of time. Importantly, the present findings are specific to sympathetic outflow directed at skeletal muscle.
All subjects in the present study were receiving ACE inhibition as baseline therapy. Nonetheless, LF MSNA spectral power was markedly decreased, or absent, prior to the co-administration of β-blockade. This observation is particularly interesting, because the beneficial impact of ACE inhibition in CHF is due primarily to attenuation of disease progression, rather than a reduction in sudden death, 37,38 whereas β-adrenoceptor antagonists have a greater impact on sudden death. 18 Experimental evidence suggests that this reduction in sudden death can be attributed primarily to central, rather than peripheral β-adrenoceptor antagonism. 39 Importantly, in the present series the average dose of carvedilol was well above the threshold demonstrated previously to reduce transcardiac NE spillover and improve survival. 40 Restoration of MSNA spectral power may represent a novel, additional mechanism by which CHF treatment with these 2 β-adrenoceptor antagonists could improve survival in general, and reduce the incidence of sudden death in particular.
